IXO+A in mCRC With Liver-only Metastases

NCT01293942 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab

Sponsor

Ottawa Hospital Research Institute

Collaborators

[object Object]
[object Object]